Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Which Oral Combination of Anti-diabetes Medication May Work Better in Subjects With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized Control Trial
Verified date | March 2022 |
Source | Getz Pharma |
Contact | Azra Rizwan, FCPS |
Phone | +923212655271 |
azra.rizwan[@]aku.edu | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin and/or DDP4 inhibitors.
Status | Recruiting |
Enrollment | 123 |
Est. completion date | November 15, 2023 |
Est. primary completion date | May 15, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Patient who give informed consent voluntarily - Type 2 diabetic patient having age from 18 years to 60 years - HbA1C = 7.0 % - Diabetes diagnosis of = 5 years (longer duration more likely to be associated with use of multiple drug regimens for glycemic control which may affect liver fat mass) - Either treatment naïve or on metformin alone or metformin/DPP4i combination - Absolute weight < 100kg; BMI < 45 (fibro scan machine cannot accommodate heavier individuals) - Documented hepatosteatosis (If the fibroscan reveals S1 (mild fatty liver: 11-33% fatty liver) to S3 (severe fatty liver: > 67% fatty liver) liver fat Exclusion Criteria: - Hba1c = 9% and/or blood sugar > 250mg/dl - History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism, or that requiring frequent dose adjustment, or Cushings syndrome) - History of anti-obesity medication use within 3 months of consent for study enrollment or weight loss procedure(bariatric surgery) within same duration - History of use of SGLT 2 inhibitors, glitazones, Glucagon-like peptide (GLP) 1 agonists 3 months prior to study enrollment as they influence liver fat - History of use of insulin/sulphonylurea 3 months prior to study enrollment owing to weight gain and potential increase in liver fat conferred by these agents - History of vitamin E use (400mg twice daily) within 3 months of study enrollment - Drug induced liver disease or active substance abuse (cannabonnoid-derived substances like heroin, cocaine, amphetamines) based on history and/or laboratory tests - Drugs known to be associated with hepatic steatosis like steroids, traditional homeopathic medication (likely to contain steroids), methotrexate, valproate, tamoxifen, amiodarone. - Alcohol use (History of alcoholism or a greater than recommended alcohol intake (> 21 standard drinks on average per week in men and > 14 standard drinks on average per week in women) - Severe hepatic impairment (ALT levels > 3 times upper limit normal) - Hepatitis B/C hepatitis (based on positive Hepatitis B surface antigen, Anti Hepatitis C antibodies positive - Autoimmune hepatitis (in case of females), based on positive Anti-nuclear Antibody (ANA) (homogenous, high titre) - Positive Human Immunodeficiency Virus ( HIV) test as this could influence liver functions - Pregnant or lactating women/ plans for pregnancy over proceeding 13 months - Obstructive liver disease on the basis of laboratory and imaging studies - Chronic renal failure, or Glomerular Filtration Rate (GFR) < 30 mls/minute (as estimated by the MDRD equation) - Chronic heart failure, history of acute coronary artery disease or cerebrovascular accident within 3 months of consent for study enrollment, based on history and/or cardiac imaging - History of recurrent Urinary Tract Infections (UTI's) or mycotic infections - Presence of ketones on Urine Analysis |
Country | Name | City | State |
---|---|---|---|
Pakistan | Aga Khan University Hospital | Karachi | Sindh |
Lead Sponsor | Collaborator |
---|---|
Getz Pharma |
Pakistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Urine Albumin to Creatinine Ratio (UACR) | Number of participants reported change in Urine Albumin to Creatinine Ratio (UACR) from baseline to end of treatment | 12 months | |
Other | Change in Systolic and Diastolic blood pressure | Number of participants reported change in Systolic and Diastolic blood pressure from baseline to end of treatment | 12 months | |
Primary | Change in radiologic liver parameters | Number of participants reported change in liver fat content from baseline, as quantified by fibroscan | 12 months | |
Secondary | Change in liver enzymes | Number of participants reported change in liver enzymes levels including ALT, AST and GGT | 12 months | |
Secondary | Change in Fibrosis-4 (FIB-4) Score and NAFLD Fibrosis Score | Number of participants reported change in FIB-4 Score and NAFLD Fibrosis Score. Fibrosis-4 scores range from 0 to 4, where <1.45 indicates absence of cirrhosis; score between 1.45 - 3.25 are deemed inconclusive and score >3.25 indicates cirrhosis. | 12 months | |
Secondary | Change in body weight | Number of participants reported change in body weight from baseline (treat to target response of at least 5% of baseline at 6 months, 10% baseline over 12 months). | 12 months | |
Secondary | Change in waist circumference (WC) | Number of participants reported change in waist circumference (WC) | 12 months | |
Secondary | Change in liver fat mass with total body fat (TBF) | Comparison of baseline and end of treatment liver fat mass with total body fat (TBF) using a Body Composition Monitor | 12 months | |
Secondary | Change in HbA1C levels (< 7.0%) | Number of participants reported change in HbA1C levels from baseline to end of treatment | 12 months | |
Secondary | Change in Fasting Blood Sugar (FBS) | Number of participants reported change in Fasting Blood Sugar (FBS) from baseline to end of treatment | 12 months | |
Secondary | Change in Lipid profile | Number of participants reported change in Fasting triglycerides (TG), Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL) from baseline to end of treatment | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |